TY - JOUR
T1 - Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry
AU - Mezghani, Nadia
AU - Yao, Alexandria
AU - Vasilyeva, Daria
AU - Kaplan, Nicole
AU - Shackelford, Austin
AU - Yoon, Angela
AU - Phillipone, Elizabeth
AU - Dubey, Sunil
AU - Schwartz, Gary K.
AU - Taylor, Alison M.
AU - Momen-Heravi, Fatemeh
N1 - Publisher Copyright:
© 2023 American Association for Cancer Research Inc.. All rights reserved.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Purpose: The purpose of this study was to better understand the complex molecular biomarkers and signatures of head and neck cancer (HNC) among Black patients and identify possible molecular changes associated with HNC disparities. Experimental Design: Molecular subtypes and genomic changes in HNC samples from patients of African and European ancestry in The Cancer Genome Atlas, Memorial Sloan Kettering Cancer Center, Broad Institute, MD Anderson Cancer Center, and John Hopkins University were identified. Molecular features (genomic, proteomic, transcriptomic) associated with race and genomic alterations associated with clinical outcomes were determined. An independent cohort of HNC tumor specimens was used to validate the primary findings using IHC. Results: Black patients were found to have a younger age at diagnosis, more aggressive tumor types, higher rates of metastasis, and worse survival compared with White patients.had fewer human papillomavirus–positive tumor types and higher frequencies of laryngeal subtype tumors. Higher frequencies of TP53, MYO18B, KMT2D, and UNC13C mutations and a lower frequency of PIK3CA mutations were observed in Black patients. Tumors of Black patients showed significant enrichment of c-MYC and RET-tyrosine signaling and amplifications. A significant increase in tumor expression of c-MYC in Black patients was observed and was associated with poor survival outcomes in the independent cohort. Conclusions: Novel genomic modifications and molecular signatures may be related to environmental, social, and behavioral factors associated with racial disparities in HNC. Unique tumor mutations and biological pathways have potential clinical utility in providing more targeted and individualized screening, diagnostic, and treatment modalities to improve health outcomes.
AB - Purpose: The purpose of this study was to better understand the complex molecular biomarkers and signatures of head and neck cancer (HNC) among Black patients and identify possible molecular changes associated with HNC disparities. Experimental Design: Molecular subtypes and genomic changes in HNC samples from patients of African and European ancestry in The Cancer Genome Atlas, Memorial Sloan Kettering Cancer Center, Broad Institute, MD Anderson Cancer Center, and John Hopkins University were identified. Molecular features (genomic, proteomic, transcriptomic) associated with race and genomic alterations associated with clinical outcomes were determined. An independent cohort of HNC tumor specimens was used to validate the primary findings using IHC. Results: Black patients were found to have a younger age at diagnosis, more aggressive tumor types, higher rates of metastasis, and worse survival compared with White patients.had fewer human papillomavirus–positive tumor types and higher frequencies of laryngeal subtype tumors. Higher frequencies of TP53, MYO18B, KMT2D, and UNC13C mutations and a lower frequency of PIK3CA mutations were observed in Black patients. Tumors of Black patients showed significant enrichment of c-MYC and RET-tyrosine signaling and amplifications. A significant increase in tumor expression of c-MYC in Black patients was observed and was associated with poor survival outcomes in the independent cohort. Conclusions: Novel genomic modifications and molecular signatures may be related to environmental, social, and behavioral factors associated with racial disparities in HNC. Unique tumor mutations and biological pathways have potential clinical utility in providing more targeted and individualized screening, diagnostic, and treatment modalities to improve health outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85149153940&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149153940&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-22-2258
DO - 10.1158/1078-0432.CCR-22-2258
M3 - Article
C2 - 36508165
AN - SCOPUS:85149153940
SN - 1078-0432
VL - 29
SP - 910
EP - 920
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 5
ER -